Totally implantable portal systems are widely used for long-term central venous access. A new venous portal system inserted via the brachial veins (P.A.S. Port™ system, Pharmacia Deltec Inc, U.S.A.) was studied in five centres.
From January 1988 through May 1989 61 systems were implanted. Fifty-two patients had malignant diseases. Nine cases had non-malignant disorders. The portals were implanted subcutaneously in the fore-arm and catheterization was done percutaneously (46) or by cutdown-technique (15) under local anesthesia. Catheter tip position was controlled by fluoroscopy or x-ray. The basilic vein (49) and the cephalic vein (12) were used. The total follow-up time for all systems was 323 months. Forty-five systems were still in use at the end of the observation period, six were explanted electively at the end of infusion therapy and six systems were still functioning at the time of the patient’s death (at a maximum of 14 months after implantation). Temporary arm-phlebitis was noticed on the first postoperative week in five patients. Two P.A.S. Port™ systems were explanted due to infection and one because of skin rupture at the wound. One intact system was removed as it was thought to be leaking because of needle displacement. The P.A.S. Port™ system is easy and safe to implant with a high success rate and a low complication rate. It is well accepted by patients and nurses. The device should be advantageous in patients unsuitable for standard venous portal systems and offers an excellent alternative system for venous access.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Brincker H, Saeter G: Fifty-five patient years’ experience with a totally implanted system for intravenous chemotherapy.Cancer 57, 1124 (1986).
Green F L, Moore W, Strickland G, McFarland J: Comparison of a totally implantable access device for chemotherapy (Port-A-Cath) and long-term percutaneous catheterization (Broviac).South Med J 81, 580 (1988).
Schuman E, Brady A, Gross G, Hayes J: Vascular access options for outpatient cancer therapy.Am J Surg 153, 487 (1987).
Gyves J W, Ensminger W D, Neiderhuber J E, Dent T, Walker S, Gilbertson S, Cozzi E, Saran P: A totally implanted injection port system for blood sampling and chemotherapy administration.JAMA 251, 2538 (1984).
Starkhammar H, Bengtsson M: Totally implanted device for venous access. Experience in tumour patients.Acta Radiol Oncol 24, 173 (1985).
Kalso E, Rosenberg P H, Vuonalho M, Pietilä K: How much do arm movements displace cubital central venous catheters?Acta Anaesth Scand 26, 354 (1982).
Linder L-E, Curelaru I, Gustavsson B, Hansson H-A, Stenqvist O, Wojciechowski J: Material thrombogeni-city in central venous catheterization: A comparison between soft, antebrachial catheters of silicone elastomer and polyurethane.J Parenter Enter Nutr 8, 399 (1984).
Bottino J, McCredie K B, Groschel D H M, Lawson M: Long-term intravenous therapy with peripherally inserted silicone elastomer central venous catheters in patients with malignant diseases.Cancer 43, 1937 (1979).
Starkhammar H, Bengtsson M, Håkansson L, Hirsch J D, Schuman E, Galen W, Gain T: Experience with a new peripherally implanted vascular access system.Proc Am Soc clin Oncol 8, 332 (1989).
About this article
Cite this article
Starkhammar, H., Bengtsson, M., Gain, T.B. et al. A new injection portal for brachially inserted central venous catheter. A multicenter study. Med. Oncol. & Tumor Pharmacother. 7, 281 (1990). https://doi.org/10.1007/BF02987107
- Drug therapy
- Vena cava-superior